Ticagrelor

Ticagrelor

CAT N°: 15425
Price:

From 48.00 40.80

Ticagrelor is a reversible antagonist of the platelet purinergic P2Y12 receptor (Ki = 14 nM; IC50 = 1.8 ?M), which is the main receptor responsible for ADP-induced platelet aggregation.{25099,23701} It functions by directly changing the conformation of the P2Y12 receptor to inhibit ADP binding.{23699} Formulations containing ticagrelor have been used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol
  • Correlated keywords
    • inhibitors platelets aggregation P2Y12 receptors antagonists purinergic antiplatelet ADP cardiovascular diseases binds binding application therapy ischemia ischemic cardiac complications cardiovascular ARC 126532XX AR C 126532XX AZD6140 AZD-6140 477283-75-3 873203-45-3 1215268-22-6 Brilinta Brilique
  • Product Overview:
    Ticagrelor is a reversible antagonist of the platelet purinergic P2Y12 receptor (Ki = 14 nM; IC50 = 1.8 ?M), which is the main receptor responsible for ADP-induced platelet aggregation.{25099,23701} It functions by directly changing the conformation of the P2Y12 receptor to inhibit ADP binding.{23699} Formulations containing ticagrelor have been used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome.

We also advise you